Rezolute Announces Positive Results from the Phase 3 upLIFT Study in Tumor Hyperinsulinism

Primary efficacy endpoint achieved based on preliminary results from a November 5th data evaluationTopline results for the completed study, along with additional study details including statistical analysis of the primary endpoint, are expected by mid-December 2026REDWOOD CITY, Calif., Nov. 13, 202…